DOCSLIB.ORG

The Effects of the Topical Administration of Non-Steroidal Anti

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The effects of the PASQUALE ARAGONA, GIULIANA TRIPODI, ROSARIA SPINELLA, topical administration EMILIA LAGANA, GIUSEPPE FERRERI of non-steroidal anti­ inflammatory drugs on corneal epithelium and corneal sensitivity in normal subjects Abstract demonstrated for the other NSAIDs when compared either with the placebo-treated eyes Purpose To study the changes in the corneal or with the fellow eyes. epithelium and corneal sensitivity of healthy Conclusions Despite a similar mechanism of subjects after the topical administration of action and analgesic activity to the other non-steroidal anti-inflammatory drugs NSAIDs tested, diclofenac was able to induce (NSAIDs; diclofenac, indomethacin, a reduction in corneal sensitivity. More flurbiprofen and ketorolad frequently used in studies are needed to determine the ocular therapy_ mechanism of action responsible for this Methods A double-masked parallel clinical effect. study was undertaken on 90 subjects (45 men, 45 women; Caucasian; age 21--46 years, mean ::':: Key words Corneal sensitivity, Diclofenac, SD 27.1 ::':: 5 years). The subjects were divided Flurbiprofen, Indomethacin, Ketorolac, Non­ into six groups: group 1 was treated with steroidal anti-inflammatory drugs placebo, group 2 with 0.1% diclofenac, group 3 with 0.1% indomethacin, group 4 with 0.03% Non-steroidal anti-inflammatory drugs flurbiprofen, group 5 with 0.5% ketorolac and (NSAlDs) act in reducing fever and alleviating group 6 with 0.4% oxybuprocaine. One eye pain that accompanies injury or inflammation. was randomly treated with the study drug and They inhibit cyclooxygenase, an enzyme the fellow eye was treated with placebo. The important for the synthesis of prostaglandins medications were instilled four times, at 5 min and certain related autacoids. The intervals. Assessment of the corneal prostaglandins, produced following injury by epithelium was carried out by vital fluorescein activation of the arachidonic acid cascade, stain before instillation and 5, 15, 30 and 60 min after instillation of the last drop. induce a state of hyperalgesia by lowering the Subjective burning sensation was assessed by threshold of activation of the pain afferent asking participants to rate burning on a scale nerves. NSAIDs act locally or near the point of P Aragona injury reducing the prostaglandin-induced G. Tripodi from 0 (none) to 3 (severe). After 1 week, R. Spinella assessment of corneal sensitivity was carried hyperalgesia.1 E. Lagana out by the Cochet-Bonnet method, repeating The topical ocular use of NSAlDs includes Ferreri G. the above scheme of instillation and maintenance of pupillary dilatation during Institute of Ophthalmology measurement times. surgery, and control of post-operative ocular University of Messina inflammation and pain, for example following Messina, Italy Results None of the study drugs, with the radial keratotomy? or photorefractive exception of oxybuprocaine, produced evident Dr Pasquale Aragona [:;!'J keratectomy.3 They are also used for the epithelial damage. All the drugs caused a Institute of Ophthalmology prevention and treatment of post-operative University of Messina mean burning sensation greater than the cystoid macular oedema 1 and for non-surgically viale Boccetta, 70 placebo. The diclofenac-treated group showed 1-98122 Messina, Italy a statistically significant decrease in corneal induced inflammatory disorders of the eye, Tel: +39 90343184 sensitivity (p < 0.001) at the measurement such as allergic conjunctivitis. A number of Fax: +39 902924819 carried out 15 min after instillation of the last different conditions, either physiological such e-mail: [email protected] drop and lasting up to the end of the study, as ageing, menstrual cycle or pathological like when the corneal anaesthesia was similar to trauma, glaucoma, hypoxia and corneal acidosis Received: 31 March 1999 Accepted in revised form: that induced by the topical anaesthetic after contact lenses wear, herpes simplex 15 September 1999 treatment. No significant changes were keratitis, diabetes, leprosy and trigeminal 206 Eye (2000) 14, 206--210 © 2000 Royal College of Ophthalmologists neuralgia,4-8 can affect corneal sensitivity. A decreased The eye drops were instilled in one eye 4 times at 5 corneal sensitivity was also described after ocular min intervals and the ocular surface studied by surgical procedures such as epikeratophakia,9 radial fluorescein stainl8 before drug instillation and 5,15, 30 keratotomylO and photo refractive keratectomy, II and and 60 min after the last drop was instilled. The fellow topical treatment with NSAIOsY-I5 eye was treated according to the same procedure, with Diclofenac sodium is a phenylacetic acid derivative the drop used in the placebo group. A subjective used, in clinical practice, for its analgesic properties. evaluation of the burning sensation was performed by Indomethacin, a methylated indole derivative, exerts its asking participants to rate burning, after each instillation, action through a prominent anti-inflammatory activity. on a scale ranging from 0 (none) to 3 (severe). Indomethacin also has an analgesic effect distinct from After 1 week the drugs were instilled again, following its anti-inflammatory properties with both a central and the same procedure previously described; the corneal peripheral action. Flurbiprofen is a propionic acid sensitivity measurements were performed before the derivative with a prevalent analgesic effect.16 Ketorolac instillation and 5, 15, 30 and 60 min after instillation of tromethamine is a member of the phenylalkanoic group the last drop, using the Cochet-Bonnet aesthesiometer of NSAIDs, which has shown marked analgesic (Luneau Ophtalmologie, Chartres, France). The properties.I7 The aim of the study was to compare the instrument consists of a 0.12 mm diameter nylon filament of variable length (from 0 to 60 mm) which is applied on effect of indomethacin, diclofenac, flurbiprofen and the cornea with a strength variable from 11 to 200 mg/ ketorolac on the corneal epithelium and on corneal 0.0113 mm2 (mg/S).19 The subjects were pOSitioned at the sensitivity of healthy volunteers. slit-lamp fixating on a distant point with the slit-lamp light positioned at about 60°, with low-intensity illumination. The measurements were started with the Material and methods filament at its maximal length (lowest pressure), which is 60 mm. The filament was advanced perpendicularly and Ninety subjects (45 men, 45 women; Caucasian; age the cornea touched gently. Measurements were taken at 21-46 years, mean ::':: SO 27.1 ::':: 5years) were enrolled in the central cornea and in the four peripheral quadrants. the study. Commercially available drugs were used. Six A positive response was registered when the subject groups each of 15 healthy volunteers, age and sex declared verbally the sensation of corneal touch. The matched, were studied. simple reflex blinking of the tested eye was not recorded Group 1, the control group, was treated with placebo as a positive response. If a positive response was not with the following solution: boric acid 99.75 mg, borax achieved the filament length was reduced by 5 mm and 7.45 mg, methyl-p-hydroxybenzoate 2.5 mg, polyethylene the procedure repeated. The filament length that glycol 400 1242.50 mg, disodium edetate 2.5 mg, purified determined the corneal sensation was registered and water quantum sufficit to 5 ml (mean age ::':: SO 28.7 ::':: 6.9 converted into milligrams/surface unit (mg/S) years; 8 women, 7 men). according to a table supplied by the instrument Group 2 was treated with 0.1 % diclofenac (Voltaren manufacturer. Ofta, Ciba Vision Ophthalmics, Hettlingen, Switzerland) The study was performed with a double-masked (26.2 ± 4 years; 7 women, 8 men). design since both the subjects and the examiner were Group 3 was treated with 0.1% indomethacin solution masked as to which eye received the drug. (Indocollirio, SIFI, Catania, Italy) (26.7 ::':: 3.6 years; 8 For statistical analysis of the results of corneal women, 7 men). epithelial damage Fisher's exact test was used; the results Group 4 was treated with 0.03% flurbiprofen (Ocufen, of corneal sensitivity (in mg/S) were carried out Allergan Pharmaceuticals, Westport, Co. Mayo, Ireland) conSidering for each eye the mean value obtained from (26.2 ± 3.3 years; 7 women, 8 men). the measurements of the five areas considered. Analysis Group 5 was treated with 0.5% ketorolac was performed using an analysis of variance. Results tromethamine (Acular, Allergan Pharmaceuticals, were expressed as the mean ::':: SO. A P value of � 0.05 Westport, Co. Mayo, Ireland) (24.9 ± 4 years; 8 women, was considered statistically significant. 7 men). Group 6 was treated with a topical anaesthetic solution Results of 0.4% oxybuprocaine chloridrate (Novesina, Novartis Farma, Orrigio (VA), Italy) (30 ::':: 6.1 years; 7 women, 8 No signs of corneal epithelial damage were found in the men). patients of the five groups treated with placebo or with Informed consent was obtained from all subjects. NSAIOs at any time of the study. Four subjects treated Exclusion criteria were: age over 50 years, contact lens with the topical anaesthetic showed mild corneal wear, and patients with present ocular diseases or with a epithelial defects (score 1 according to Lempl8) already history of diseases such as herpetic diseases or with present at 5 min after instillation of the last drop and previous ocular surgery. Also excluded were patients lasting up to the observation at 60 min (p = 0.04). who had taken topical or general treatment during the All groups instilled with NSAIDs complained of a previous month or with systemic diseases such as mild burning sensation lasting a few seconds after each diabetes. instillation. The grading of the subjective burning 207 3 200 T T 1# 170 2.5 " " ,t " 20 I - 2 t:' 18 !!! - - - ! 16 8 1.5 f-- f-- til � 14 - - - f-- r--- E 12 10 T - - - r---- I- 0.5 ' Before 5' 15' 30 60' Time a � / C Placebo 61Dlcloten.c atIndomethacm 0 Flurblprofen Ketorolac0 CAn.esthetic Fig. 2. Mean decrease in corneal sensitivity in the diclofenac-treated 2 group, expressed as an increase in weightlsurface unit (0.0113 mm ) Fig.
Recommended publications
  • Studies in Laboratory Animals to Assess the Safety of Anti-Inflammatory Agents in Acute Porphyria

    Studies in Laboratory Animals to Assess the Safety of Anti-Inflammatory Agents in Acute Porphyria

    Ann Rheum Dis: first published as 10.1136/ard.46.7.540 on 1 July 1987. Downloaded from Annals of the Rheumatic Diseases, 1987; 46, 540-542 Studies in laboratory animals to assess the safety of anti-inflammatory agents in acute porphyria KENNETH E L McCOLL, GEORGE G THOMPSON, AND MICHAEL R MOORE From the University Department of Medicine, Western Infirmary, Glasgow SUMMARY The safety of various anti-inflammatory drugs in acute porphyria was assessed by examining their effect on rat hepatic haem synthesis. Azapropazone, chloroquine, and gold increased 6-aminolaevulinic acid (ALA) synthase activity, indicating that they are liable to precipitate porphyric crises. Aspirin, ibuprofen, indomethacin, ketoprofen, flurbiprofen, phenylbutazone, naproxen, prednisolone, and penicillamine did not increase ALA synthase activity and should be safe in porphyria. Though these animal studies can be used as a guide to prescribing in patients with acute porphyria, some caution is still required as species may vary in their response to inducing agents. Key words: chloroquine, azapropazone, gold, b-aminolaevulinic acid synthase. copyright. The acute hepatic porphyrias which comprise acute controlling enzyme of haem biosynthesis 6- intermittent porphyria, hereditary coproporphyria, aminolaevulinic acid (ALA) synthase in rat hepatic and variegate porphyria are examples of pharma- tissue. To confirm the reliability of the animal cogenetic disease. They are the result of deficien- model, phenobarbitone was also tested. For each cies of individual enzymes in the pathway of haem drug examined six male Sprague-Dawley rats re- biosynthesis and are inherited in an autosomal ceived the test drug and six control rats received the dominant fashion.2 Subjects with the genetic trait appropriate placebo solution.
  • Drug-Induced Peptic Ulcer Disease

    Drug-Induced Peptic Ulcer Disease

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by OAR@UM risk populations only.7 The prevalence of endoscopically confirmed gastrointestinal ulcers in NSAID users is quoted to be between 15% and 30%. Between 12% to 30% of NSAID-induced ulcers are gastric ulcers, whereas 2% to 19% are duodenal ulcers. NSAID-induced ulcers are symptomatic only in 1% of patients after three to six months and in 2 to 4% of patients after one year. Inappropriately they do not correlate well with pain because the analgesic action of NSAIDs may mask the ulcer pain.2 Drug-induced peptic Understanding the method by which NSAIDs cause gastric damage has helped in the development of prophylactic agents that ulcer disease 1 red uce their toxicity. The mechanism by which NSAIDs are thought to damage the Valerie Vella B Pharm(Hons), PgDip Clin Pharm (Aberdeen) gastrointestinal tract is four-fold. Clinical Pharmacist, St Luke’s Hospital, Guardamangia, Malta a) Topical injury Email: [email protected] Originally it was thought that NSAIDs damaged the gastric epithelium by Key words: Peptic ulcer, medicines, prostaglandins, gastrointestinal protection, intracellular accumulation of these drugs in gastrointestinal toxicity an ionised state.1 However the fact that enteric-coated formulations, pro-drugs, For more than a century, peptic ulcer disease has been a rectal and parenteral administration of 1 major cause of morbidity and mortality. Peptic ulcer disease NSAIDs still resulted in gastrointestinal is a heterogeneous group of disorders involving the damage despite the apparent absence of gastrointestinal tract and results from an imbalance between direct mucosal contact implies a minor role the aggressive forces of gastric acid and pepsin and the for topical injury1,2.
  • CELEBREX™ (Celecoxib Capsules)

    CELEBREX™ (Celecoxib Capsules)

    01/05/99 4:16 PM draft label 1 CELEBREX™ 2 (celecoxib capsules) 3 4 5 DESCRIPTION 6 7 CELEBREX (celecoxib) is chemically designated as 4-[5-(4-methylphenyl)-3- 8 (trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide and is a diaryl substituted 9 pyrazole. It has the following chemical structure: 10 O NH2 S O N N CF3 11 CH3 12 13 14 The empirical formula for celecoxib is C17H14F3N3O2S, and the molecular weight is 381.38. 15 16 CELEBREX oral capsules contain 100 mg and 200 mg of celecoxib. 17 18 The inactive ingredients in CELEBREX capsules include: croscarmellose sodium, edible 19 inks, gelatin, lactose monohydrate, magnesium stearate, povidone, sodium lauryl sulfate 20 and titanium dioxide. 21 22 CLINICAL PHARMACOLOGY 23 24 Mechanism of Action 25 CELEBREX is a nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, 26 analgesic, and antipyretic activities in animal models. The mechanism of action of 27 CELEBREX is believed to be due to inhibition of prostaglandin synthesis, primarily via 28 inhibition of cyclooxygenase-2 (COX-2), and at therapeutic concentrations in humans, 29 CELEBREX does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme. 30 31 Pharmacokinetics 32 33 Absorption 34 Peak plasma levels of celecoxib occur approximately 3 hrs after an oral dose. Both peak 35 plasma levels (Cmax) and area under the curve (AUC) are roughly dose proportional 36 across the clinical dose range of 100-200 mg studied. At higher doses, under fasting 37 conditions, there is a less than proportional increase in Cmax and AUC which is thought 38 to be due to the low solubility of the drug in aqueous media.
  • Colonoscopy Instructions

    Colonoscopy Instructions

    Colonoscopy Checklist Five days before your colonoscopy: Stop any medications that thin the blood (see list below) Discuss the discontinuation of these medications with your primary care physician to ensure that it is safe to stop them Three days before your colonoscopy: Stop eating high fiber foods including nuts, corn, popcorn, raw fruits, vegetables, and bran Stop fiber supplements The day before your colonoscopy: Have a normal breakfast If your colonoscopy is scheduled before noon the following day, do not have any lunch If your colonoscopy is scheduled after noon, have a light lunch Have clear liquids for the rest of the day (see below) Start prep as instructed by your physician Do not have anything to eat or drink after midnight The day of your colonoscopy: Take your blood pressure medications with a sip of water Make sure you bring your driver’s license or photo ID and leave valuables and jewelry at home Clear Liquid Diet Water Any kind of soft drink (ginger ale, cola, tonic, etc) Gatorade Apple Juice Orange Juice without pulp Lemonade Tea/Coffee (without milk) Dietary supplements (Ensure, Boost, Enlive, etc) Clear broth (vegetable, chicken, or beef) Jell‐O (stay away from red, blue, or purple colors) Ice pops without milk or fruit bits Honey or sugar NO DAIRY PRODUCTS Medications to stop prior to colonoscopy Below is a list of many medications (but not all) that fall into these categories. It is important to remember that there are hundreds of over‐the‐counter medications that contain NSAIDs or aspirin, so it is important to carefully read the label of any medication that you are taking (prescription or over‐the‐counter).
  • Diclofenac Topical Patch Gel Solution Monograph

    Diclofenac Topical Patch Gel Solution Monograph

    Diclofenac Topical Patch, Gel and Solution National Drug Monograph March 2016 VHA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Action Diclofenac is the only nonsteroidal antiinflammatory drug (NSAID) approved in the U.S. for topical application. The mechanism of diclofenac is believed to be inhibition of prostaglandin synthesis, primarily by nonselectively inhibiting cyclooxygenase. The agents covered in this review are the four diclofenac topical products approved for analgesic purposes: Diclofenac epolamine / hydroxyethylpyrrolidine patch (DEHP) 1.3% approved in January 2007 Diclofenac sodium topical gel 1%, approved in October 2007 Diclofenac sodium topical solution 1.5% with dimethyl sulfoxide (DMSO, 45.5% w/w), approved in November 2009 Diclofenac sodium topical solution 2% with dimethyl sulfoxide (DMSO, 45.5% w/w), approved in January 2014 Indication(s) Under Review in this document (may include off Solution 1.5% Solution 2% label) Patch 1.3% Gel 1% (Drops) (MDP) Topical treatment Relief of the pain of Treatment of signs Treatment of the Also see Table 1 Product Descriptions of acute pain due osteoarthritis of joints and symptoms of pain of below. to minor strains, amenable to topical osteoarthritis of the osteoarthritis of sprains, and treatment, such as the knee(s) the knee(s) contusions knees and those of the hands.
  • Diclofenac Sodium Enteric-Coated Tablets) Tablets of 75 Mg Rx Only Prescribing Information

    Diclofenac Sodium Enteric-Coated Tablets) Tablets of 75 Mg Rx Only Prescribing Information

    ® Voltaren (diclofenac sodium enteric-coated tablets) Tablets of 75 mg Rx only Prescribing Information Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS.) • Voltaren® (diclofenac sodium enteric-coated tablets) is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS.) DESCRIPTION Voltaren® (diclofenac sodium enteric-coated tablets) is a benzene-acetic acid derivative. Voltaren is available as delayed-release (enteric-coated) tablets of 75 mg (light pink) for oral administration. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The molecular weight is 318.14. Its molecular formula is C14H10Cl2NNaO2, and it has the following structural formula The inactive ingredients in Voltaren include: hydroxypropyl methylcellulose, iron oxide, lactose, magnesium stearate, methacrylic acid copolymer, microcrystalline cellulose, polyethylene glycol, povidone, propylene glycol, sodium hydroxide, sodium starch glycolate, talc, titanium dioxide. CLINICAL PHARMACOLOGY Pharmacodynamics Voltaren® (diclofenac sodium enteric-coated tablets) is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Voltaren, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.
  • Be Aware of Some Medications

    Be Aware of Some Medications

    Aspirin, Pain Relievers, Cold and Fever Remedies and Arthritis Medications when you have asthma, rhinitis or nasal polyps For some people with asthma, rhinitis and nasal polyps, medications such as acetylsalicylic acid or ASA and some arthritis medications can trigger very severe asthma, rhinitis, hives, swelling and shock. If you react to one of these medications, you will probably react to all of the others as well. There are many medications and products that contain ASA. This handout names some. Since new products are coming out all of the time, it is best to check with the pharmacist before using. Check the label yourself as well. If you react to these medications you must: Avoid these medications and products at all times. Let your doctor know right away if you have taken one of the medications and develop symptoms. Check the ingredients on the label yourself. Ask your pharmacist, doctor or other health care provider if you have questions. Get a medical alert bracelet or card that says you are allergic to ASA. Tell all of your health care providers that you are allergic to ASA. For pain control, use acetaminophen. Some products with acetaminophen are Atasol, Tempra, Tylenol and Novo-Gesic. Most people allergic to ASA can use acetaminophen. Firestone Institute for Respiratory Health St. Joseph’s Hospital McMaster University Health Sciences Some Products that Contain ASA 217s, 217s Strong D P 222s Doan’s Backache Pills Pepto-Bismol 282s, 282s Meps Dodd’s Tablets – All Percodan 292s Dolomine 37 Phenaphen with Codeine 692s Dristan Extra Strength PMS-Sulfasalazine A Dristan – All kinds AC&C R AC&C Extra Strength E Ratio-Oxycodan Acetylsalicylic Acid EC ASA Relief ASA Achrocidin Ecotrin – All kinds Robaxisal – All kinds Aggrenox Endodan Alka Seltzer – All kinds Enteric coated ASA S Anacin – All kinds Enteric coated aspirin Salazopyrin Antidol Entrophen – All kinds Salazopyrin Enema Apo-ASA Excedrin Salofalk Enema Apo-Asen Sulfasalazine Arco Pain Tablet F Arthrisin Fiorinal T Artria SR Fiorinal with Codeine Tri-Buffered ASA ASA, A.S.A.
  • Arthritis Treatment Comparison Arthritis Treatment Comparison

    Arthritis Treatment Comparison Arthritis Treatment Comparison

    ARTHRITIS TREATMENT COMPARISON ARTHRITIS TREATMENT COMPARISON GENERIC OA of (BRAND) HOW SUPPLIED AS GA JIA JRA OA Knee PsA RA CHELATING AGENTS Penicillamine Cap: 250mg ✓ (Cuprimine) Penicillamine Tab: 250mg ✓ (Depen) CYCLIC POLYPEPTIDE IMMUNOSUPPRESSANTS Cyclosporine Cap: 25mg, 100mg; ✓ (Gengraf, Neoral) Sol: 100mg/mL CYCLOOXYGENASE-2 INHIBITORS Celecoxib Cap: 50mg, 100mg, ✓ ✓ ✓ ✓ (Celebrex) 200mg, 400mg DIHYDROFOLIC ACID REDUCTASE INHIBITORS Methotrexate Inj: 25mg/mL; ✓ ✓ Tab: 2.5mg Methotrexate Tab: 5mg, 7.5mg, ✓ ✓ (Trexall) 10mg, 15mg INTERLEUKIN RECEPTOR ANTAGONISTS Anakinra Inj: 100mg/0.67mL ✓ (Kineret) Tocilizumab Inj: 20mg/mL, ✓ ✓ (Actemra) 162mg/0.9mL GOLD COMPOUNDS Auranofin Cap: 3mg ✓ (Ridaura) Gold sodium thiomalate Inj: 50mg/mL ✓ ✓ (Myochrysine) HYALURONAN AND DERIVATIVES Hyaluronan Inj: 30mg/2mL ✓ (Orthovisc) Sodium hyaluronate Inj: 1% ✓ (Euflexxa) Sodium hyaluronate Inj: 10mg/mL ✓ (Hyalgan) Sodium hyaluronate Inj: 2.5mL ✓ (Supartz) HYLAN POLYMERS Hylan G-F 20 Inj: 8mg/mL ✓ (Synvisc, Synvisc One) KINASE INHIBITORS Tofacitinib Tab: 5mg ✓ (Xeljanz) MONOCLONAL ANTIBODIES Ustekinumab Inj: 45mg/0.5mL, ✓ (Stelara) 90mg/mL MONOCLONAL ANTIBODIES/CD20-BLOCKERS Rituximab Inj: 100mg/10mL, ✓ (Rituxan) 500mg/50mL (Continued) ARTHRITIS TREATMENT COMPARISON GENERIC OA of (BRAND) HOW SUPPLIED AS GA JIA JRA OA Knee PsA RA MONOCLONAL ANTIBODIES/TNF-BLOCKERS Adalimumab Inj: 20mg/0.4mL, ✓ ✓ ✓ ✓ (Humira) 40mg/0.8mL Golimumab Inj: 50mg/0.5mL, ✓ ✓ ✓ (Simponi) 100mg/mL Infliximab Inj: 100mg ✓ ✓ ✓ (Remicade) NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
  • Efficacy of Ketoprofen Vs. Ibuprofen and Diclofenac: a Systematic Review of the Literature and Meta-Analysis P

    Efficacy of Ketoprofen Vs. Ibuprofen and Diclofenac: a Systematic Review of the Literature and Meta-Analysis P

    Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis P. Sarzi-Puttini1, F. Atzeni1, L. Lanata2, M. Bagnasco2 1Rheumatology Unit, L. Sacco University Hospital, Milan, Italy; 2Medical Department, Dompé SpA, Milan, Italy. Abstract Objective The aim of this systematic review of the literature and meta-analysis of randomised controlled trials (RCTs) was to compare the efficacy of orally administered ketoprofen with that of ibuprofen and/or diclofenac. Methods The literature was systematically reviewed in accordance with the Cochrane Collaboration guidelines. The search was restricted to randomised clinical trials published in the Medline and Embase databases up to June 2011, and comparing the efficacy of oral ketoprofen (50–200 mg/day) with ibuprofen (600-1800 mg/day) or diclofenac (75–150 mg/day). Results A total of 13 RCTs involving 898 patients met the inclusion criteria: eight comparing ketoprofen with ibuprofen, and five comparing ketoprofen with diclofenac. The results of the meta-analysis showed a statistically significant difference in efficacy in favour of ketoprofen. The difference between ketoprofen and the pooled ibuprofen/diclofenac data was also statistically significant (0.459, 95% CI 0.33-0.58; p=0.00) at all point-estimates of the mean weighted size effect. Ketoprofen was significantly superior to both diclofenac (mean = 0.422; 95% CI 0.19-0.65; p=0.0007) and ibuprofen (mean = 0.475; 95% CI 0.32-0.62; p=0.0000) at all point-estimates. Heterogeneity for the analysed efficacy outcome was not statisically significant in any of the meta-analyses. Conclusion The efficacy of orally administered ketoprofen in relieving moderate-severe pain and improving functional status and general condition was significantly better than that of ibuprofen and/or diclofenac.
  • Of 20 PRODUCT MONOGRAPH FLURBIPROFEN Flurbiprofen Tablets BP 50 Mg and 100 Mg Anti-Inflammatory, Analgesic Agent AA PHARM

    Of 20 PRODUCT MONOGRAPH FLURBIPROFEN Flurbiprofen Tablets BP 50 Mg and 100 Mg Anti-Inflammatory, Analgesic Agent AA PHARM

    PRODUCT MONOGRAPH FLURBIPROFEN Flurbiprofen Tablets BP 50 mg and 100 mg Anti-inflammatory, analgesic agent AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road, Unit #1 April 16, 1991 Vaughan, Ontario L4K 4N7 DATE OF REVISION: February 7, 2019 Submission Control No. 223098 Page 1 of 20 PRODUCT MONOGRAPH NAME OF DRUG FLURBIPROFEN Flurbiprofen Tablets BP 50 mg and 100 mg PHARMACOLOGICAL CLASSIFICATION Anti-inflammatory, analgesic agent ACTIONS AND CLINICAL PHARMACOLOGY FLURBIPROFEN (flurbiprofen), a phenylalkanoic acid derivative, is a non-steroidal anti- inflammatory agent which also possesses analgesic and antipyretic activities. Its mode of action, like that of other non-steroidal anti-inflammatory agents, is not known. However, its therapeutic action is not due to pituitary adrenal stimulation. Flurbiprofen is an inhibitor of prostaglandin synthesis. The resulting decrease in prostaglandin synthesis may partially explain the drug's anti-inflammatory effect at the cellular level. Pharmacokinetics: Flurbiprofen is well absorbed after oral administration, reaching peak blood levels in approximately 1.5 hours (range 0.5 to 4 hours). Administration of flurbiprofen with food does not alter total drug availability but delays absorption. Excretion of flurbiprofen is virtually complete 24 hours after the last dose. The elimination half-life is 5.7 hours with 90% of the half-life values from 3-9 hours. There is no evidence of drug accumulation and flurbiprofen does not induce enzymes that alter its metabolism. Flurbiprofen is rapidly metabolized and excreted in the urine as free and unaltered intact drug (20-25%) and hydroxylated metabolites (60-80%). In animal models of inflammation the metabolites showed no activity.
  • A COMPARATIVE STUDY of FLURBIPROFEN and ASPIRIN in SOFT TISSUE TRAUMA Accident Service, Radcliffe Infirmary, Oxford Surgeon

    A COMPARATIVE STUDY of FLURBIPROFEN and ASPIRIN in SOFT TISSUE TRAUMA Accident Service, Radcliffe Infirmary, Oxford Surgeon

    Br J Sports Med: first published as 10.1136/bjsm.10.1.11 on 1 March 1976. Downloaded from 11 A COMPARATIVE STUDY OF FLURBIPROFEN AND ASPIRIN IN SOFT TISSUE TRAUMA David S. MUCKLE, M.B., B.S., F.R.C.S., M.S. Accident Service, Radcliffe Infirmary, Oxford Surgeon and Medical Adviser to Oxford United F. C. ABSTRACT A double blind study using flurbiprofen (2-(2-fluoro-4-biphenylyl propionic acid) 150 mg daily and soluble aspirin (3.6 g daily) for 5 days immediately after injury, was carried out in 52 soft tissue injuries to the lower limb in professional sportsmen. Flurbiprofen was more effective than aspirin in producing analgesia (when daily pain scores were considered) after day 2 (p < 0.02); and flurbiprofen produced a more effective resolution of soft tissue trauma when days to training and match play were considered (p < 0.05). The inhibitory effects of flurbiprofen on prostaglandin biosynthesis and tissue action are mentioned and the use of anti-inflammatory agents given immediately after soft tissue injuries discussed. Introduction level of pain (mild, moderate or severe) according to instructions outlined on the jacket of the pack, and the In a previous double blind study using a phenylal- appropriate square was marked. The injured area was kanoic acid, "Brufen", (ibuprofen (2-(4-iso-butylphenyl) observed daily by the trainer or club doctor and all signs propionic acid) 1,200 mg daily) and soluble aspirin (3.0 recorded. The dates to full training and match fitness g daily) it was shown that the immediate use of these were noted.
  • Topical Pharmaceutical Compositions of Flurbiprofen and Methyl Salicylate

    Topical Pharmaceutical Compositions of Flurbiprofen and Methyl Salicylate

    (19) & (11) EP 2 455 074 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.05.2012 Bulletin 2012/21 A61K 31/05 (2006.01) A61K 47/10 (2006.01) A61K 9/00 (2006.01) (21) Application number: 11187973.0 (22) Date of filing: 04.11.2011 (84) Designated Contracting States: • Türkyilmaz, Ali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 34398 Istanbul (TR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Akalin, Nur Pehlivan PL PT RO RS SE SI SK SM TR 34398 Istanbul (TR) Designated Extension States: • Önder, Ramazan BA ME 34398 Istanbul (TR) • Öner, Levent (30) Priority: 08.11.2010 TR 201009220 Ankara (TR) (71) Applicant: Sanovel Ilac Sanayi ve Ticaret A.S. (74) Representative: Sevinç, Erkan 34398 Istanbul (TR) Istanbul Patent & Trademark Consultancy Ltd. Plaza-33, Büyükdere cad. No: 33/16, Sisli (72) Inventors: 34381 Istanbul (TR) • Cifter, Ümit 34398 Istanbul (TR) (54) Topical pharmaceutical compositions of flurbiprofen and methyl salicylate (57) The present invention relates to topical pharma- thermore, the invention relates to process for preparing ceutical compositions comprising flurbiprofen or a phar- the said topical pharmaceutical compositions and its use maceutically acceptable salt thereof and methyl sali- for the treatment of pain and inflammatory symptoms as- cylate. More specifically, the invention relates to topical sociated with muscle-skeletol system, joint and soft-tis- pharmaceutical compositions of flurbiprofen and methyl sue disorders. salicylate characterized in that said composition compris- es dimethyl sulfoxide and one or more gelling agent.